Spyre Therapeutics, Inc. (NASDAQ:SYRE) is among the 14 best booming stocks to buy right now. On January 5, Wells Fargo reiterated a Buy rating on the stock, with a price target of $40. Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating The update follows Mizuho’s initiation of coverage on the stock on December 18 with an Outperform rating and a share price target of$53, where it cited potential in the company’s pipeline of anti-monoclonal antibodies to treat inflammatory bowel ...